InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement ...

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

Treatment of PG is currently limited to immune-suppressing drugs and antibiotics to treat complicating infections, and, in ...

Clinical appearances were consistent with pyoderma gangrenosum. The patient has a history of complicated pyoderma gangrenosum, having undergone skin grafts 14 years prior, for ulcers on her lower legs ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

German drug developer InflaRx (Nasdaq: IFRX) saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it ...